14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $84.70 $93.35 Monday, 22nd Apr 2024 BMRN stock ended at $89.49. This is 0.97% more than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 1.03% from a day low at $88.89 to a day high of $89.81.
90 days $83.44 $94.51
52 weeks $76.02 $99.55

Historical BioMarin Pharmaceutical Inc. prices

Date Open High Low Close Volume
Nov 27, 2023 $87.73 $89.11 $87.64 $88.60 1 803 562
Nov 24, 2023 $88.69 $89.37 $88.14 $88.19 343 184
Nov 22, 2023 $88.81 $88.81 $87.42 $88.42 1 304 999
Nov 21, 2023 $87.46 $88.59 $86.87 $88.06 1 450 929
Nov 20, 2023 $87.33 $88.57 $87.07 $87.53 3 122 375
Nov 17, 2023 $87.18 $87.88 $86.71 $87.52 1 725 280
Nov 16, 2023 $87.14 $88.20 $85.93 $87.21 2 875 501
Nov 15, 2023 $84.78 $87.87 $84.41 $87.06 2 928 256
Nov 14, 2023 $84.83 $85.89 $84.43 $84.86 1 402 144
Nov 13, 2023 $83.18 $83.88 $82.55 $83.39 1 235 585
Nov 10, 2023 $83.76 $84.65 $82.94 $83.98 2 515 763
Nov 09, 2023 $85.65 $85.70 $83.61 $83.72 2 498 352
Nov 08, 2023 $85.38 $85.99 $83.52 $85.51 2 575 482
Nov 07, 2023 $82.88 $86.50 $81.92 $85.49 5 209 247
Nov 06, 2023 $79.37 $79.37 $76.19 $76.22 2 010 441
Nov 03, 2023 $80.16 $80.49 $79.05 $79.59 2 390 170
Nov 02, 2023 $81.00 $81.54 $76.02 $79.67 4 444 474
Nov 01, 2023 $81.75 $84.27 $81.75 $84.01 1 775 021
Oct 31, 2023 $80.82 $81.62 $80.11 $81.45 1 733 762
Oct 30, 2023 $80.32 $81.71 $80.14 $80.98 1 934 405
Oct 27, 2023 $81.56 $81.93 $80.24 $80.67 1 504 302
Oct 26, 2023 $81.60 $82.42 $81.17 $81.97 929 654
Oct 25, 2023 $83.35 $83.35 $81.40 $81.77 539 363
Oct 24, 2023 $83.42 $83.93 $82.63 $83.35 739 925
Oct 23, 2023 $82.68 $83.47 $81.65 $82.84 819 496
Click to get the best stock tips daily for free!

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT